Biontech Se 6-K Filing
Ticker: BNTX · Form: 6-K · Filed: Dec 9, 2025 · CIK: 1776985
| Field | Detail |
|---|---|
| Company | Biontech Se (BNTX) |
| Form Type | 6-K |
| Filed Date | Dec 9, 2025 |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 6-K filing submitted by Biontech Se (ticker: BNTX) to the SEC on Dec 9, 2025.
How long is this filing?
Biontech Se's 6-K filing is 1 pages with approximately 291 words. Estimated reading time is 1 minutes.
Where can I view the full 6-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 291 words · 1 min read · ~1 pages · Grade level 16.9 · Accepted 2025-12-09 07:25:15
Filing Documents
- form6-kpumitamigsabcs9dec2.htm (6-K) — 14KB
- a991251209_bntxbmsxprxpumi.htm (EX-99.1) — 36KB
- image_0.jpg (GRAPHIC) — 102KB
- image_1.jpg (GRAPHIC) — 87KB
- 0001776985-25-000071.txt ( ) — 311KB
From the Filing
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a16 OR 15d16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF DECEMBER 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant's name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20F or Form 40F Form 20F Form 40F Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(1) Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(7) DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K On December 9, 2025, BioNTech SE (Nasdaq BNTX, "BioNTech") and Bristol Myers Squibb Company (NYSE BMY, "BMS") announced the first interim data from a global randomized Phase 2 trial (NCT06449222) evaluating pumitamig (BNT327BMS986545), an investigational bispecific antibody targeting PD-L1 and VEGF-A, plus chemotherapy in patients with locally advancedmetastatic triple-negative breast cancer ("TNBC") irrespective of PD-L1 expression levels. The press release is attached hereto as Exhibit 99.1. SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By s Ramon Zapata-Gomez By s Dr. Sierk Poetting Name Ramon Zapata-Gomez Name Dr. Sierk Poetting Title Chief Financial Officer Title Chief Operating Officer Date December 9, 2025 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer